Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11766MR)

This product GTTS-WQ11766MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ11766MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3113MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ10440MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ1628MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-910
GTTS-WQ12418MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NI-0401
GTTS-WQ6290MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ5753MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ4746MR IVTScrip™ mRNA-Anti-SOST, BPS-804(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BPS-804
GTTS-WQ4523MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW